Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Study data from C. Dulsat and co-authors update knowledge of cancer vaccines
December 31st, 2008
"Non-small cell lung cancer (NSCLC) accounts for approximately 75% of all lung cancers, the leading cause of cancer-related deaths in both men and women worldwide. Advances in vaccine therapy strategies, designed to stimulate an immune response against tumor cells, are becoming increasingly important for NSCLC patients," scientists in Barcelona, Spain report. "L-BLP-25 (Stimuvax (R)) is a new vaccine candidate for NSCLC that targets tumor-specific MUC-1 antigens, which are overexpressed and exposed due to underglycosylation in neoplastic tissues. L-BLP-25 benefits from an adjuvant that primes the immune system and facilitates uptake of the vaccine and a liposomal...
Source: Vaccine Weekly (2008-12-31)
|
